Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025)
Fennec Pharmaceuticals (FENC) posted Cost of Revenue of $1.8 million for Q4 2025, up 167.27% on a QoQ basis from $660000.0 in Q3 2025, and up 163.68% year-over-year from $669000.0 in Q4 2024.
Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $1.8 million for Q4 2025.
- Quarterly Cost of Revenue rose 163.68% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 18.22% YoY) and the FY2025 annual result came in at $3.8 million, up 18.22% from the prior year.
- Cost of Revenue was $1.8 million for Q4 2025 at Fennec Pharmaceuticals, up from $660000.0 in the prior quarter.
- Across five years, Cost of Revenue topped out at $1.8 million in Q4 2025 and bottomed at $95000.0 in Q1 2023.
- A 3-year average of $683916.7 and a median of $634000.0 in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue surged 478.95% — and 2025, when it sank 51.36%.
- Fennec Pharmaceuticals' Cost of Revenue stood at $685000.0 in 2023, then decreased by 2.34% to $669000.0 in 2024, then jumped by 163.68% to $1.8 million in 2025.
- Business Quant data shows FENC's Cost of Revenue at $1.8 million in Q4 2025, $660000.0 in Q3 2025, and $967000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 121.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Fennec Pharmaceuticals | 287.77 Mn | 250.98 Mn | 12.01 Mn | 1.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 660,000.00 |
| Sep 30, 2025 | 660,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Mar 31, 2025 | 373,000.00 |
| Mar 31, 2025 | 373,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 608,000.00 |
| Jun 30, 2024 | 608,000.00 |
| Mar 31, 2024 | 550,000.00 |
| Mar 31, 2024 | 550,000.00 |
| Dec 31, 2023 | 685,000.00 |
| Dec 31, 2023 | 685,000.00 |
| Sep 30, 2023 | 331,000.00 |
| Sep 30, 2023 | 331,000.00 |